FDA Endocrinologic & Metabolic Drugs Advisory Committee
Executive Summary
On July 24, the committee will discuss the osteoporosis indication of Rhone-Poulenc Rorer's Calcimar (injectable salmon calcitonin) "in light of recently acquired efficacy data." In March, the committee declined to recommend approval for Norwich Eaton's Didronel PMO (etidronate) for osteoporosis after a follow- up study showed a 50% increase in new vertebral fractures during the third year of treatment ("The Pink Sheet" March 11, p. 3). On July 25, the committee will discuss safety and efficacy of Miles' Glucobay (acarbose), an alpha-glucosidase inhibitor for diabetes. The meetings will start at 9 a.m. both days at the Holiday Inn Crowne Plaza, Regency Room, 1750 Rockville Pike, Rockville, MD.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth